Why Scholar Rock Stock Wilted on Wednesday

Scholar Rock (SRRK) shares fell over 5% after the company reported a second-quarter net loss exceeding $110 million, or $0.98 per share, significantly wider than analyst estimates of $0.66 per share, primarily due to a near tripling of general and administrative expenses. Despite the financial shortfall, the company announced that the FDA accepted its Biologics License Application (BLA) for apitegromab, an investigational drug for spinal muscular atrophy, with a decision expected by September 22, and affirmed its $295 million in cash and equivalents provide sufficient liquidity into 2027.

Analysis

Scholar Rock (SRRK) experienced a share price decline of over 5% following its second-quarter report, which revealed a significant bottom-line miss. The company posted a net loss of over $110 million, or $0.98 per share, substantially wider than the consensus analyst estimate of a $0.66 per share loss and nearly double the $59 million deficit from the prior-year period. This deeper loss was primarily attributed to a near-tripling of general and administrative expenses to almost $50 million and a 47% increase in research and development spending. However, this negative financial performance was counterbalanced by two critical positive developments. The company affirmed a strong liquidity position with $295 million in cash and equivalents, providing a sufficient cash runway to fund operations into 2027, mitigating near-term financing concerns. More importantly, Scholar Rock announced the FDA's acceptance of its Biologics License Application (BLA) for apitegromab, its investigational drug for spinal muscular atrophy, setting a clear, near-term catalyst with a regulatory decision deadline of September 22.

Key Decisions for Investors

• Investors should recognize that SRRK's value proposition is currently dominated by the binary outcome of the FDA's decision on apitegromab by September 22, which will likely serve as a more significant catalyst than the recent earnings miss.
• The substantial increase in operating expenses is a key risk factor to monitor, but the stated cash runway into 2027 provides a crucial buffer, allowing the company to reach the pivotal regulatory milestone without immediate dilution risk.
• Given the high-stakes regulatory event, positions in SRRK are exposed to significant volatility, and a prudent strategy would involve sizing positions to account for a wide range of potential outcomes, from BLA approval leading to a sharp rally to a rejection causing a substantial decline.